Crizotinib/Xalkori medical insurance reimbursement conditions

Crizotinib/Crizotinib is a multi-target protein kinase inhibitor for patients with anaplastic lymphoma kinase (ALK) and ROS1-positive non-small cell lung cancer (NSCLC). Due to its significant clinical efficacy, crizotinib attracted widespread attention after being launched in the United States in 2011. In China, crizotinib has also been included in the scope of medical insurance, but reimbursement needs to meet certain conditions.

Crizotinib’s medical insurance reimbursement requires patients to provide reports and test results related to ALK or ROS1-positive non-small cell lung cancer confirmed by a doctor. This is because crizotinib is primarily used to treat these specific types of lung cancer. Overseas, crizotinib has also been approved for other conditions, such as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT), and its efficacy has been confirmed.

In order to ensure that crizotinib is effective and necessary for patients, medical insurance reimbursement also requires that patients must have tried other treatments (such as surgery, radiotherapy, chemotherapy, etc.) or cannot tolerate other treatments before receiving crizotinib treatment. This is because crizotinib is usually used as a second- or third-line treatment and is only considered when other treatments are ineffective or intolerable to the patient.

In addition, medical insurance reimbursement for crizotinib also needs to consider the patient’s financial status. In some countries or regions, only patients whose family income is below a certain standard can enjoy medical insurance reimbursement. This is to ensure that patients with financial difficulties can also receive necessary treatment. Currently, the original crizotinib drug that is marketed in China and included in medical insurance has different reimbursement ratios in different regions and different specifications, so the price after reimbursement will also be different.